| 38th week of 2022 patent applcation highlights part 9 |
| Patent application number | Title | Published |
|---|
| 20220296486 | Minoxidil Adjuvant Therapies - Compositions and methods are disclosed herein for inducing (up-regulating) the expression of sulfotransferases in the hair follicles, e.g., the scalp. Increasing sulfotransferase is beneficial for metabolizing pro-drugs that require sulfonation to be activated, e.g., minoxidil sulfate is the active metabolite of minoxidil. A method for combining the compositions described herein with topical minoxidil to enhance minoxidil treatment for androgenetic alopecia is described. Additional methods and compositions include the use of retinoid X receptor agonists, retinoic acid receptor agonists, and nuclear receptor agonists in an RXR-NR heterodimer. Additional methods and compositions include the use of a topical solution containing an alkalinizing agent or an alkalinizing agent used with a penetration enhancer for up-regulating the sulfonating capacity of hair bearing skin, hair follicles, and/or keratinocyte cells. In addition, compositions and methods for increasing or decreasing the growth rate of hair follicles is disclosed by altering the intracellular pH. Additionally, methods for preparing a stable liposomal containing solution are described. | 2022-09-22 |
| 20220296487 | SILICONE SUBSTITUTE NATURAL ADDITIVE COMPOSITION, PROCESS FOR OBTAINING THE SAME AND ITS USE - A natural additive composition capable of replacing silicone components in a wide variety of types of application, preferably in the field of cosmetic, veterinary cosmetic, dermocosmetic products has, in terms of percent by weight of the total weight of the composition: (a) 0.5% to 80% polysaccharides, monosaccharides and derivatives thereof; (b) 10% to 99.5% monohydric alcohols, polyhydric alcohols, unsaturated aliphatic alcohols, glycerides; and (c) 0% to 40% components depending on the type of application, which can be abrasives, emollients, rheology modifiers, moisture absorbers, etc. | 2022-09-22 |
| 20220296488 | COMPOSITIONS COMPRISING AT LEAST ONE COMPOUND OF THE N-ACYLAMINO AMIDE FAMILY AND AT LEAST ONE ALKYL POLYGLYCOSIDE - The invention relates to a composition, in particular a cosmetic composition, preferably in the form of an oil-in-water emulsion, comprising: at least one compound of the family of N-acylamino amides of formula (I); [Chem 10] at least one alkyl polyglycoside of formula (IV) below: R9(0)(G)x (iv) in which the radical R9 is a linear or branched C14-C24 alkyl radical, G represents a reduced sugar comprising from 5 to 6 carbon atoms; and x denotes a value ranging from 1 to 10 and preferably from 1 to 4. In particular, said composition also comprises at least one compound chosen from oxyethylenated sorbitan esters and fatty acid esters of a polyoxyalkylene glycol. Use for caring for, making up and/or cleansing keratin materials, in particular the skin. | 2022-09-22 |
| 20220296489 | PEPTIDES HAVING INHIBITORY ACTIVITY ON NEURONAL EXOCYTOSIS - The invention relates to peptides capable of inhibiting neuronal exocytosis and to products comprising such peptides, in particular pharmaceutical and cosmetic products useful for ameliorating skin conditions, disorders and/or diseases mediated by neuronal exocytosis, such as wrinkles, excessive perspiration, pruritus, cutaneous inflammation, dermatitis, atopia, psoriasis, vascular hyperreactivity, rosacea, acne, hair growth, wound healing, calluses, warts, or sensitive skin conditions, such as ulcers and lesions on the skin. | 2022-09-22 |
| 20220296490 | Oral Care Products and Methods - Provided herein are oral care compositions comprising partially hydrolyzed plant protein, which are useful in methods of repairing or inhibiting dental erosion, promoting dental remineralization, and/or enhancing the anti-cavity effects of fluoride. | 2022-09-22 |
| 20220296491 | Personal Care Compositions - Described herein are personal care compositions comprising—inter alia—a gum system comprising a plurality of natural gums; a surfactant system comprising a plurality of alkyl polyglucoside surfactants; and a cosmetically acceptable carrier. Methods of making and using these compositions are also described herein. | 2022-09-22 |
| 20220296492 | TOPICAL COSMETIC COMPOSITION, USE OF THE COMPOSITION AND SERUM FOR APPLYING ON THE FACE - The present invention is a topical cosmetic composition that helps to reduce and control oiliness of the skin immediately and lastingly, and also to reduce the size of pores, to reduce visual imperfections and to moisturize. The composition helps to maintain a natural healthy microbiota of the skin. The present invention pertains to the field of cosmetic science, and more specifically relates to preparations for treating the skin. | 2022-09-22 |
| 20220296493 | PARTICULARLY NATURAL OIL SUBSTITUTE FOR COSMETIC PREPARATIONS - Use of a mixture of a) hydroxypropyl starch phosphate (INCI: Hydroxypropyl Starch Phosphate) and b) esters of caprylic acid and/or capric acid as a substitute for mineral oils and silicone oils in cosmetic preparations and to their use in cosmetic preparations. | 2022-09-22 |
| 20220296494 | PARTICULARLY NATURAL OIL SUBSTITUTE FOR COSMETIC PREPARATIONS - Use of a mixture of a) hydroxypropyl starch phosphate (INCI: Hydroxypropyl Starch Phosphate) and b) vegetable oils as a substitute for mineral oils and silicone oils in cosmetic preparations and use thereof in cosmetic preparations. | 2022-09-22 |
| 20220296495 | DEODORANT COMPOSITIONS - This disclosure relates to topical personal care compositions comprising one or more of a yeast component; a | 2022-09-22 |
| 20220296496 | TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS - A method comprising topically applying to skin a composition comprising an aqueous, alcoholic, or aqueous-alcoholic extract from | 2022-09-22 |
| 20220296497 | SWERTIA CHIRATA EXTRACT AND COSMETIC COMPOSITIONS COMPRISING SAME | 2022-09-22 |
| 20220296498 | COMPOSITION CONTAINING EXTRACT OF LILIUM HANSONII LEICHTLIN EX BAKER - An extract of | 2022-09-22 |
| 20220296499 | COSMETIC USE OF ENGINEERED POSTBIOTICS COMPRISING BACTERIOCINS AND/OR ENDOLYSINS - The present invention concerns a method for the cosmetic caring of the skin and/or mucosa, comprising applying a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, wherein said postbiotic is preferably a bacterial lysate preferably obtained from bacteria heterologously expressing said at least one bacteriocin and/or endolysin and wherein said postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the cosmetic caring method. | 2022-09-22 |
| 20220296500 | Method and System for Preventing Sore Throat in Humans - A method and system to prevent sore throat infections in humans includes the administration of an active ingredient to a site on the mucus membranes of the throat of a human that inhibits adherence and promotes desorption of | 2022-09-22 |
| 20220296501 | ORAL COMPOSITION WITH POLYMERIC COMPONENT - The disclosure provides oral compositions including at least one active ingredient and a polymeric component, the oral compositions having a moisture content of at least about 10% by weight, based on total weight of the oral composition. The polymeric component includes a natural gum, a food grade polymer, or a combination thereof. The natural gum may be a non-galactomannan polysaccharide; a galactomannan polysaccharide selected from fenugreek gum, tara gum, locust bean gum, | 2022-09-22 |
| 20220296502 | NON-AQUEOUS PATCH - Non-aqueous patches comprising lidocaine, which is not dissolved and is present in a crystalline state, have poor permeability to the skin. Therefore, non-aqueous patches have a high concentration of lidocaine. It is pointed out that lidocaine has an adverse effect on the heart. Prolonged use of a high concentration of lidocaine causes side effects, such as shock, rubor, and irritating sensation. External preparations comprising more than 5 mass % of lidocaine are designated as powerful drugs, and cannot be used as household (nonprescription) medicine. Provided is a non-aqueous patch that is effective to relieve muscle pain, the non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent composed of an organic acid and a polyalcohol, which are contained in a base. | 2022-09-22 |
| 20220296503 | DELAYING PEAK EFFECT AND/OR EXTENDING DURATION OF RESPONSE - The present disclosure describes certain technologies for administering large agent(s) (e.g., biologically active large agents such as biologic therapeutics including, for instance, botulinum toxin) to subjects, including technologies that achieve unexpected results such as, for example, delayed peak effect and/or extended duration of response. | 2022-09-22 |
| 20220296504 | INTRANASAL DELIVERY OF LEVODOPA POWDER BY PRECISION OLFACTORY DEVICE - Methods are provided for treating OFF episodes in a patient with Parkinson's disease or a Parkinson syndrome, comprising administering to a subject with Parkinson's disease or a Parkinson syndrome experiencing an OFF episode an effective dose of a dry pharmaceutical composition comprising L-DOPA, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma levodopa concentration (C | 2022-09-22 |
| 20220296505 | IMMUNOSTIMULATORY METHOD - This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety. | 2022-09-22 |
| 20220296506 | A METHOD FOR OBTAINING ION-EXCHANGE POLYMERIC HYDROGELS FOR EYE TREATMENT AND HYDROGEL LENSES THEREOF - The present invention could be used in medicine and relates to a method of producing ion-exchange polymeric hydrogels for eye treatment, which includes monomer copolymerization under ionizing radiation in presence of linking agent and ionites, when copolymerization is carried out gradually to obtain a prepolymer of desired viscosity for filling lens forms, and ionites introduction in the form of finely dispersed powder, filing the hydrogel into lens forms and subsequent copolymerization till an adequate ionizing dosage is performed providing a gel suitable for lenses formation, characterized in that the gel is also filled with pharmaceutically active agent in the form of finely dispersed powder prior to ionite introduction, and the size of particles of PAA is lower that the size of ionite particles. The present invention also relates to therapeutic hydrogel lenses produced in accordance with the above-mentioned method. | 2022-09-22 |
| 20220296508 | NICOTINE POUCH - The disclosure provides chewable nicotine formulations comprising an orally-acceptable nicotine salt, an orally-acceptable alcohol, flavor components, and an orally-acceptable binder in a water-permeable, water-insoluble pouch, together with methods of making and using the same. | 2022-09-22 |
| 20220296509 | ORAL COMPOSITION INCLUDING GELS - The disclosure provides for an oral composition containing a gel. The gel may be formed of a long chain carbohydrate, such as an alginate, that is crosslinked with a suitable crosslinking agent. Other material, such as fillers, active ingredients, flavor components, and the like may be included in the gel or otherwise combined with the gel to form an oral product. The disclosure further provides methods of preparing oral compositions. | 2022-09-22 |
| 20220296510 | SELF-SIZING DEVICE FOR DELIVERING A FORMULATION TO A LUMEN WALL - A system is provided for delivering a therapeutic formulation into a lumen. The system includes a self-sizing device comprising an expandable component that includes at least one non-compliant section structured to resist deformation in an expanded configuration, the expandable component further including at least one hinge structured to allow deformation in an expanded configuration, the expandable component structured to bend about the hinge upon expansion to adapt to an inner circumference of a lumen independent of the inner circumference of the lumen within a selected range. The system includes the therapeutic formulation and a delivery mechanism. The self-sizing device is structured to, upon expansion of the expandable component, cause the delivery mechanism to apply a force to the therapeutic formulation, the force designed to expel the therapeutic formulation from the self-sizing device. The self-sizing device may be disposed within a capsule. | 2022-09-22 |
| 20220296511 | COMPOSITIONS FOR DELIVERY OF DRUG COMBINATIONS TO TREAT LUNG DISEASE - In some aspects, the present disclosure provides pharmaceutical compositions comprising particles, wherein individual particles of the composition comprise a combination of two or more active pharmaceutical ingredients selected from:
| 2022-09-22 |
| 20220296512 | GEL FOR TREATING PERIOCULAR AND/OR ORBITAL PATHOLOGIES AND CONDITIONS - A method comprising treating a periocular wound in a subject, comprising topically administering to the periocular wound a composition comprising at least one thermoresponsive gel. | 2022-09-22 |
| 20220296513 | MICROEMULSION MIXTURE AND METHOD OF USING THE SAME, AND PHARMACEUTICAL MICROEMULSION MIXTURE AND METHOD OF USING THE SAME - The present invention provides a microemulsion mixture, comprising a microemulsion and an active ingredient, wherein the microemulsion comprises a water phase composite, comprising a water solution and a moisturizer; an oil phase composite; and a surfactant composite; and the active ingredient is the substrate of cytochrome P450 3A4 enzyme. The microemulsion of the present invention inhibits the expression of the cytochrome P450 3A4 enzyme so as to improve the efficacy of the active ingredient in the microemulsion mixture. The present invention further provides a method of using the microemulsion mixture, a pharmaceutical microemulsion mixture comprising the microemulsion mixture, and the method for treating psoriasis comprising administering the microemulsion mixture to a subject in need thereof. | 2022-09-22 |
| 20220296514 | Composition and Method of Preparation for Lipid Formulations Comprising Charged Lipids - A lipid-based nanoparticle (LNP) with high DL ratio and normalized release. The LNP of the present invention comprises an outer lipid monolayer encapsulating a plurality of lipid-active pharmaceutical ingredient (API)-ion complexes, wherein each lipid-API-ion complex comprises a complex of anionic lipid, API and ion wherein the API comprises a positively charged form of an API and wherein the outer lipid monolayer of the LNP comprises neutral lipids. The present invention further comprises a method of preparation of the LNP of the present invention. | 2022-09-22 |
| 20220296515 | Vancomycin Liposome Compositions and Methods - The inventive subject matter is directed to compositions and methods for liposomal vancomycin that have improved pharmacokinetics and enhanced drug loading and solution stability. | 2022-09-22 |
| 20220296516 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES - Provided are delivery vehicles, and methods of making and using same for reaching epithelial cells, such as cells within mucus-containing environments, and delivery vehicles with improved stability in harsh environments, including in the gastrointestinal tract. | 2022-09-22 |
| 20220296517 | COMPOSITIONS AND METHODS FOR ENHANCED DELIVERY OF AGENTS - The disclosure features target cell delivery lipid nanoparticle (LNP) compositions that allow for enhanced delivery of agents, e.g., nucleic acids, such as therapeutic and/or prophylactic RNAs, to target cells, in particular liver cells and/or splenic cells. The LNPs comprise an effective amount of a target cell delivery potentiating lipid such that delivery of an agent by a target cell target cell delivery LNP is enhanced as compared to an LNP lacking the target cell delivery potentiating agent. Methods of using the target cell target cell delivery LNPs for delivery of agents, e.g., nucleic acid delivery, for protein expression, and for modulating target cell activity are also disclosed. | 2022-09-22 |
| 20220296518 | LIPID-BASED NANOPARTICLE DELIVERY SYSTEM FOR HYDROPHILIC CHARGED COMPOUND - A lipid-based nanoparticle (LNP) with high DL ratio and normalized release. The LNP of the present invention comprises an outer lipid monolayer encapsulating a plurality of lipid-active pharmaceutical ingredient (API) complexes, wherein each lipid-API complex comprises a complex of anionic lipid and API wherein the API comprises a positively charged form of an API and wherein the outer lipid monolayer of the LNP comprises neutral lipids. The present invention further comprises a method of preparation of the LNP of the present invention. | 2022-09-22 |
| 20220296519 | PROTEIN STABILIZED LIPOSOMES (PSL) AND METHODS OF MAKING THEREOF - Compositions and methods for synthesis of protein stabilized liposomes (PSLs) is described. In one aspect, a protein excipient that stabilizes liposome integrity, when incorporated into liposome formulations, is provided. The manufacturing process for production of metastable liposome particles with a half-life of several months is also described. In some aspects the liposome particles may contain a bioactive agent. In some cases, the bioactive agent is a protein, nucleic acid, lipid, or small molecule. | 2022-09-22 |
| 20220296520 | LIPOSOME COMPOSITION AND PREPARATION METHOD THEREOF - The present disclosure provides methods for preparing a liposome composition. One of the methods includes the steps of: providing precursor liposomes encapsulating platinum-based precursors; and incubating the precursor liposomes with a salt solution to convert the platinum-based precursors to platinum-based drugs to form the liposome composition. The precursor liposomes are prepared by step of: hydrating the platinum-based drugs to form the platinum-based precursors; and adding the platinum-based precursors to a lipid bilayer vehicle to form the precursor liposomes. The liposome composition prepared by the methods shows improved encapsulation efficiency and enhanced drug loading capacity. | 2022-09-22 |
| 20220296521 | CARRIER-BASED FORMULATIONS AND RELATED METHODS - Provided herein are carrier-based dry powder formulations to be administered as dry powders for inhalation and that enable improved targeting within the respiratory tract (e.g., to the lower respiratory tract) of patients. The carrier-based dry powder formulations described herein have a desired size and impaction parameter that promotes targeted delivery of formulations to regions of the lungs and reduce the loss of drugs in the formulation to deposition in other regions of the respiratory tract (e.g., URT). Also provided herein are methods of producing the formulations, methods of making the formulations, and methods of aerosolizing and using the formulations to treat disease. | 2022-09-22 |
| 20220296522 | BRYOID COMPOSITIONS, METHODS OF MAKING AND USE THEREOF - Embodiments of the present invention are directed to drug delivery systems, dosage forms and methods for the intranasal administration of Bryostatins for the treatment of neuro-degenerative diseases. Inventions of the present application are directed to the treatment of neuro-degenerative diseases such as Hutchinson Disease, Parkinson's disease, Down syndrome and Alzheimer's disease. | 2022-09-22 |
| 20220296523 | SINGLE-INJECTION METHODS AND FORMULATIONS TO INDUCE AND CONTROL MULTIPLE OVARIAN FOLLICLES IN BOVINE, CAPRINE, OVINE, CAMELID AND OTHER FEMALE ANIMALS - Methods and formulations for a simplified, single-injection method to induce and control the synchronous growth (superstimulation), and ovulation (superovulation) of multiple ovarian follicles in bovine, ovine, caprine, camelid and other female animals enabling the subsequent collection of (a) multiple oocytes when conducting in-vitro fertilization, or (b) multiple embryos when conducting multiple ovulation embryo transfer. | 2022-09-22 |
| 20220296524 | INITIAL BURST RELEASE CONTROLLED DEPOT COMPOSITION AND A METHOD THEREOF - A depot composition including a hydrophobic amino acid in a microsphere is provided. The depot composition is capable of controlling the initial burst release of an excess amount of the active ingredient in a formulation including a biodegradable polymer and an active ingredient. The depot composition has excellent suspending ability, and is able to uniformly and continuously obtain the effect of the active ingredient even when an ordinary user uses the composition as a formulation for injection. | 2022-09-22 |
| 20220296525 | METHOD FOR PRODUCING A BIOACTIVE COMPONENT-CONTAINING NANO-COMPOSITE, AND A MONTMORILLONITE-BASED, BIOACTIVE COMPONENT-CONTAINING NANO-COMPOSITE - The present invention relates to a method for producing a bioactive component-containing nanocomposite, specifically a method for producing a montmorillonite-based, bioactive component-containing nanocomposite, as well as to a montmorillonite-based nanocomposite containing a bioactive component, particularly curcumin or dexketoprofen. | 2022-09-22 |
| 20220296526 | CANNABINOID COMPOSITIONS, METHODS OF MAKING SAME AND USES THEREOF - The present disclosure relates to cannabinoid compositions that are rehydratable and that upon such rehydration retain at least some of the properties of the original cannabinoid emulsions from which the cannabinoid composition was obtained. In particular, to cannabinoid compositions formed by spray drying of an emulsion, the composition comprising at least one cannabinoid, a carrier oil, one or more emulsifiers, and a sugar carrier, where the composition has a water activity that is less than about 0.5. The emulsion may include a nanoemulsion, a microemulsion, or both a nanoemulsion and a microemulsion. The present disclosure also relates to method of manufacturing same. | 2022-09-22 |
| 20220296527 | FIXED DOSE PHARMACEUTICAL COMPOSITION OF VALSARTAN AND SACUBITRIL - This present invention relates to pharmaceutical composition comprising fixed dose combination of valsartan or pharmaceutically acceptable salts thereof and sacubitril or pharmaceutically acceptable salts thereof. Further this invention also relates to process for the preparation of said composition and use of the said composition in treatment of certain diseases. | 2022-09-22 |
| 20220296528 | PHARMACEUTICAL COMPOSITIONS OF BERBERINE WITH EPA AND DHA, AND METHODS THEREOF - The invention provides various novel compositions of berberine in combination with pharmacologically active EPA and DHA, and related methods of their use in treating various diseases or disorders. The pharmaceutical compositions of the invention are useful in treating and/or preventing various diseases or disorders, including metabolic diseases or disorders such as dyslipidemia, hyperglycemia, hypertriglyceridemia, hyperlipidemia, diabetic dyslipidemia, diabetic hyperlipidemia, dyslipidemia in statin-intolerance patients, diabetes, diabetic complications, hypercholesterolemia, or obesity. Additionally, the pharmaceutical compositions of the invention are useful in treating and/or preventing atherosclerosis, heart diseases, neurodegenerative diseases, inflammation, cancers, as well as various liver diseases or disorders, such as fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, cholestatic liver diseases or graft-versus-host disease of the liver. Furthermore, the pharmaceutical compositions of the invention are useful in improving liver functions in chronic viral associated liver diseases and alcohol-related liver diseases. | 2022-09-22 |
| 20220296529 | PRE-FILLING SYSTEM TO ELIMINATE BUBBLES INSIDE CAPSULES HAVING A SOLID DOSAGE FORMS WITHIN SAID CAPSULES - The invention provides a rotary die mold process for manufacturing softgel capsules incorporating another solid form within said capsule and wherein said softgel capsule is free of air bubbles, in which at least two material strips are brought together by means of counter-running forming rolls and formed into capsules, a liquid and solid filling material being introduced via a filling wedge segment comprising two concave wedge surfaces; a filling medicine inlet; a fill medicine outlet; an output of solids and pre-fill medicine; a solids feed channel and pre-fill medicine; a pre-filling medicine inlet and a solids inlet. A softgel capsule free of air bubbles having incorporated within said capsule a second solid form, said second solid form being the form of a tablet. | 2022-09-22 |
| 20220296530 | VAPOR PHASE COATINGS FOR PHARMACEUTICAL SOLUBILITY CONTROL - A method of preparing a pharmaceutical composition having a drug-containing core enclosed by one or more metal oxide materials is provided. The method includes the sequential steps of (a) loading the particles comprising the drug into a reactor, (b) applying a vaporous or gaseous metal precursor to the particles in the reactor, (c) performing one or more pump-purge cycles of the reactor using inert gas, (d) applying a vaporous or gaseous oxidant to the particles in the reactor, and (e) performing one or more pump-purge cycles of the reactor using inert gas. The temperature of the particles does not exceed 35° C. This produces a pharmaceutical composition comprising a drug containing core enclosed by one or more metal oxide materials. | 2022-09-22 |
| 20220296531 | Method for Adjusting the Release of Active Agent in a Transdermal Delivery System - Use of an additive in a transdermal therapeutic system with an active agent-containing layer in the form of a biphasic layer having a hydrophilic inner phase and a hydrophobic outer phase, in which the inner phase comprises the additive and an active agent dissolved therein, the additive has a higher affinity to water than to the active agent, for the control of the permeation rate of the active agent in a manner which is independent from its concentration in the biphasic layer, with the maintenance of the permeation rate proportional to the amount of active agent in the biphasic layer. | 2022-09-22 |
| 20220296532 | COMPOSITION FOR DELIVERING NITRIC OXIDE TO SKIN - A skin application composition comprising a first component in dry condition comprising a source of nitrite and a thiol and a second component comprising a source of water is provided. | 2022-09-22 |
| 20220296533 | COMPOSITIONS AND METHODS FOR INCREASING INTRACELLULAR GLUCOSE UPTAKE - A method for increasing intracellular glucose uptake by administering a composition comprising at least one Glut-4 expression inducement agent in combination with an antioxidant, an amino acid, and a vasodilator. | 2022-09-22 |
| 20220296534 | SCYLLO-INOSITOL AND B-CELL MEDIATED DISORDERS - The present invention relates generally to the field of β-cell mediated disorders. In particular, the present invention relates to scyllo-inositol for use in the treatment or prevention of disorders linked to an impaired function of insulin secreting β-cells. The present invention further relates to scyllo-inositol for use in the treatment or prevention of a condition or symptom associated with such disorders in a subject. | 2022-09-22 |
| 20220296535 | Antibacterial Dosage Regime Using Cannabinoids - The present invention provides methods, compositions and uses for treating topical bacterial infections comprising the administration of cannabinoids. In particular, the present invention provides methods, uses and compositions for treating bacterial infections, the compositions comprising cannabidiol or other cannabinoids, in a dose ranging from about 25 mg to about 500 mg of the cannabinoid compounds. | 2022-09-22 |
| 20220296536 | PAIN MANAGEMENT METHODOLOGY - A pain management system and methodology for preventing or alleviating chronic pain, and/or pain associated with a medical procedure prior to the medical procedure being performed, includes (a) aurally isolating a patient for a chosen period shortly prior to the patient receiving propofol in accordance with step (c), (b) exposing the patient to a repetitive, positive message during the chosen period, and (c) subsequently administering an effective quantity of propofol to the patient. For step (b), the repetitive, positive message may be delivered from a pre-recorded memory card inserted in headphones. | 2022-09-22 |
| 20220296537 | NOVEL PHARMACEUTICAL COMPOSITIONS - The invention relates to pharmaceutical compositions comprising dopamine transporter inhibitors and to their use in the prophylaxis or treatment of disease states or conditions mediated by the dopamine transporter. | 2022-09-22 |
| 20220296538 | Substituted Tolans for the Modulation of Microbial Colonization - Described are methods for disinfecting a physical or biological surface by contact with an antimicrobial formulation comprising a substituted tolan compound, the substitutions being, for example, one or more alkoxy, (e.g., methoxy) and hydroxy substituents at one or both phenyl rings of the tolan. The compounds and methods are -static and/or -cidal, depending on dose and suspected microbe. Suspected pathogenic microbes include Gram negative bacteria, such as | 2022-09-22 |
| 20220296539 | METFORMIN GLYCINATE, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME - The present disclosure relates to metformin glycinate and methods of using metformin glycinate for the treatment of diseases including diabetes mellitus, obesity, dyslipidemia, diseases associated with IL-10 up-regulation, and diseases or disorders associated with elevated or increased ceramide levels. Pharmaceutical formulations comprising metformin glycinate are also disclosed. | 2022-09-22 |
| 20220296540 | SYNERGISTIC BIOACTIVE COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS - The present invention disclosed herein relates to synergistic bioactive compositions for treating neurological disorders. Particularly, the invention relates to anti-ischemic nutritional compositions. More particular, the invention relates to synergistic, efficient, nutritional compositions for treating cerebral ischemia comprising therapeutically active exogenous combination of a decarboxylated L-arginine called agmatine (AGM) and a bio-optimized palmitoylethanolamide (Bio-PEA) and salts thereof, wherein the decarboxylated L-arginine salt i.e., agmatine sulfate and bio-optimized palmitoylethanolamide (PEA) are present in a weight ratio of 1:0.1 to 1:5 along with pharmaceutically acceptable excipients. | 2022-09-22 |
| 20220296541 | N-PALMITOYL-ETHANOLAMIDE FOR USE IN THE PREVENTION OF COLORECTAL CARCINOMA - Described herein is a use of N-palmitoylethanolamide in the context of an antitumor therapy, in particular, a use of Palmitoylethanolamide in the prevention of colorectal carcinoma, adenomatous polyps, and/or pre-neoplastic ACF lesions. Also described herein are palmitoylethanolamide for use in the antineoplastic therapy of colorectal carcinoma, in which the palmitoylethanolamide exerts a selective antiproliferative action on tumor cells and not on healthy cells. | 2022-09-22 |
| 20220296542 | METHOD FOR IMPROVING DIGESTIVE HEALTH - Disclosed herein are methods for improving digestive health by providing a consumable composition. Some embodiments provided include, for example, administering a compound of Formula (I) or compound of Formula (II). Some embodiments provide the composition is formulated as a dietary supplement, food ingredient or additive, a medical food, nutraceutical or pharmaceutical composition. | 2022-09-22 |
| 20220296543 | METHODS AND COMPOSITIONS FOR PREVENTING SKIN TOXICITIES CAUSED BY BIOLOGICAL TARGETED CANCER DRUGS - Provided are methods for inhibiting binding of systemically administered drugs to a target in the skin by topically administering materials prior to or concomitantly with administration of the systemic drugs. | 2022-09-22 |
| 20220296544 | NANOEMULSION OF 18BETA-GLYCYRRHETINIC ACID - The invention refers to pharmaceutical forms that potentiate the bioavailability of 18β-GA, having a high permeation on the application area mainly due to the effect of their small particle size, high concentration of the active ingredient, excipient composition, micelles with specific structural composition and polarity. The present pharmaceutical forms exhibit specific values for particle size, permeability, diffusion coefficient, and polydispersity helping to provide its technical advantages. Therapeutic uses of the pharmaceutical forms are also described, which include those therapeutic uses for which 18β-glycyrrhetinic acid is known to have an effect, such as anti-inflammatory, antiviral, antibacterial activity, hepatoprotective, used against skin diseases and anticarcinogenic. Mainly gelled solutions, emulsions and nanoemulsions, are intended for application in the vaginal and cervical area, for the treatment of diseases related to the human papillomavirus, such as infections, lesions, and cervical cancer. | 2022-09-22 |
| 20220296545 | METHODS AND COMPOSITIONS INCLUDING PROTOCATECHUIC ACID CRYSTALS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS - In embodiments, a method of treating a disease or condition caused by Respiratory Syncytial Virus in a mammal is disclosed including administering to the mammal a composition comprising protocatechuic acid crystals. The mammal may be a human. The composition may include a pharmaceutically acceptable carrier. | 2022-09-22 |
| 20220296546 | Methods Of Treatment Of Inflammation Related Conditions Using Pluripotent Anti-inflammatory And Metabolic Modulators - Methods of treating acute and chronic inflammatory conditions, tissue transplant rejection, and/or organ transplant rejection comprising administering to a subject in need thereof a therapeutically effective amount of a pluripotent anti-inflammatory and metabolic modulators optionally in combination with one or more secondary therapeutic agents and pharmaceutical compositions thereof. | 2022-09-22 |
| 20220296547 | METHODS AND COMPOSITIONS FOR TREATMENT OF DISEASES - In an embodiment, the present disclosure relates to a method of ameliorating or preventing a disease or disease condition. Generally, the method includes administering a composition having a synthetic lysine analog, derivative, or mimetic. In some embodiments, the synthetic lysine analog, derivative, or mimetic interacts with cells associated with the disease or disease condition to inhibit or prevent replication, survival, or formation of the cells. In another embodiment, the present disclosure relates to a composition having a synthetic lysine analog, derivative, or mimetic for ameliorating or preventing a disease or disease condition. In a further embodiment, the present disclosure is related to a method and composition having a synthetic lysine analog, derivative, or mimetic for ameliorating aging. In an additional embodiment, the present disclosure is related to a method and composition having a synthetic lysine analog, derivative, or mimetic for treatment and prevention of cancer. | 2022-09-22 |
| 20220296548 | PREVENTATIVE OR THERAPEUTIC AGENT FOR TAUOPATHY - A prophylactic or therapeutic agent for tauopathy, containing an inhibitor of α | 2022-09-22 |
| 20220296549 | Small Molecule Agents, Compositions, and Formulations, for Internal Use, Displaying Inhibitory Activity Against Gram-positive and/or Gram-negative Organisms - Active components comprising lauric acid, or a lauric acid derivative, are utilized independently, or in combination, to provide new and useful compositions for bacteriostatic action against susceptible pathogens. The lauric acid derivative includes one or more of 12-aminododecanoic acid, 12-amino-1-dodecanoic acid methyl ester, sucrose monolaurate, 12-(7-nitrobenzofurazan-4-ylamino) dodecanoic acid, 4-nitrophenyl dodecanoate, 1-lauroyl-rac-glycerol, 3-oxo-N-(2-oxocyclohexyl) dodecanamide, butyl laurate, benzyl laurate, isoamyl laurate, monolaurin, isopropyl laurate, pentyl laurate, and hexyl laurate. A preparation includes combining the active component with lecithin, and after an initial processing phase, coating with chitosan or a carrier. Final compositions may be or may contain particles, such as nanoparticles. Final compositions, or formulations containing said final compositions, may be utilized internally, causing one or more membrane changes (e.g., a membrane of an internal target pathogen, which may or may not be an antibiotic-resistant pathogen). At least some compositions inhibit growth of one or more Gram-positive bacterial species and one or more Gram-negative bacterial species. | 2022-09-22 |
| 20220296550 | COMPOSITIONS AND METHODS TO POTENTIATE MUSCULOSKELETAL EFFECT OF ONE OR MORE ANABOLIC AMINO ACIDS - A method of potentiating musculoskeletal effect of one or more anabolic amino acids in an individual in need thereof can include administering to the individual in need thereof a composition containing the one or more anabolic amino acids, the composition also containing one or more autophagy-inducing compounds in a total amount effective for the composition to be at least neutral regarding autophagy. In another aspect, a method of overcoming one or more negative effects of one or more anabolic amino acids by preventing degenerative processes related to loss of autophagy can include administering to an individual in need thereof a composition containing the one or more anabolic amino acids, the composition further containing the one or more autophagy-inducing compounds in a total amount effective for the composition to be at least neutral regarding autophagy. | 2022-09-22 |
| 20220296551 | COMPOSITION FOR THE TREATMENT OF MUSCLE WASTING - The present invention relates to compositions comprising branched-chain amino acids (BCAA) and the amino acid L-Alanine and their use in the prevention and/or treatment of muscle wasting associated to pathological or age-related conditions. | 2022-09-22 |
| 20220296552 | COMPOSITIONS AND METHODS FOR ACUTELY RAISING NITIC OXIDE LEVELS - Disclosed herein are compositions and methods for acutely raising nitric oxide levels in a subject. In one example, the composition can include, an effective amount of a NOS dependent source of nitric oxide; an effective amount of a NOS independent source of nitric oxide; and an effective amount of a myeloperoxidase inhibitor; wherein the composition acutely raises nitric oxide levels in a subject above a level provided by the available sources of nitric oxide in the subject prior to administration of the composition. Further presented is a method of treating a subject for a condition or disorder that is response to nitric oxide therapy, including: acutely raising nitric oxide levels in a subject by simultaneously increasing biosynthesis of nitric oxide, increasing nitrate/nitrite levels, and inhibiting meyloperoxidase activity. | 2022-09-22 |
| 20220296553 | COMPOSITIONS FOR TREATING FUNGAL AND BACTERIAL BIOFILMS AND METHODS OF USING THE SAME - The disclosure provides compositions comprising amino acids, individually and in combination, and methods of making the compositions and methods of using the compositions as pharmaceutically active agents to, inter alia, treat disease in animals, including humans. | 2022-09-22 |
| 20220296554 | TREATMENT OF IDIOPATHIC HYPOHIDROSIS - The present invention provides a new treatment for idiopathic hypohidrosis. In one embodiment, the said treatment comprises administering to a patient in need a pharmaceutically effective amount of a retinoid. Preferably, the retinoid is isotretinoin or acitretin. | 2022-09-22 |
| 20220296555 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE - Disclosed herein are acylated active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker. | 2022-09-22 |
| 20220296556 | HIGHLY WATER-SOLUBLE SALTS OF A SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKER AND USES THEREOF - The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia. | 2022-09-22 |
| 20220296557 | COMBINATIONS OF BCL-2/BCL-XL INHIBITORS AND RELATED USES - The present disclosure relates to combinations of Compound No. 1 or a pharmaceutically acceptable salt thereof and at least one additional therapeutic agent. The present disclosure also relates to methods of treating or preventing a disease via administering to subjects in need thereof Compound No. 1 or a pharmaceutically acceptable salt thereof and at least one additional therapeutic agent. | 2022-09-22 |
| 20220296558 | COMPOSITIONS FOR IMPROVING BRAIN HEALTH AND MEMORY - The present disclosure relates to oral compositions that include at least two agents selected from: agents that increase the concentration of glutamate; agents that increase dopamine production; agents that increase the concentration of brain-derived neurotrophic factor (BDNF); NMDA and/or AMPA receptor modulators; and acetylcholinesterase inhibitors. In son embodiments, a composition as provided herein includes D-glutamine present in an amount of about 20% to about 30% w/w of the composition; ginkgolide B present in an amount of about 0.1% to about 0.4% w/w of the composition; phosphatidylserine present in an amount of about 65% to about 80% w/w of the composition; and ascorbic acid present in an amount of about 0.5% to about 2.5% w/w of the composition. Such compositions are useful for improving memory and/or focus. | 2022-09-22 |
| 20220296559 | Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI) - The present invention is related to pharmaceutical formulations and methods of treating a subject afflicted with the influenza virus, the method includes administering to the respiratory tract of the patient particles that include more than about 5% to about 50% weight percent (wt %) of a neuraminidase inhibitor. The particles are delivered to the patient's pulmonary system, including the upper airways, central airways and deep lung. | 2022-09-22 |
| 20220296560 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION IN POWDER FORMULATION CONTAINING ANTIVIRAL AGENT - Provided is a pharmaceutical composition for oral administration in the form of powder obtained by a process including: (a) preparing an emulsion including zanamivir as an active ingredient; triglyceride; acyl glycerol; a nonionic surfactant; a sugar; and water; and (b) lyophilizing the emulsion prepared in the step (a). The pharmaceutical composition according to the presently claimed subject matter can significantly increase in vivo absorption rate of zanamivir. Further, the pharmaceutical composition according to the presently claimed subject matter is in the form of powder, which not only make it easy to store and distribute but also make it possible to avoid the use of functional packaging materials for preventing changes in moisture. | 2022-09-22 |
| 20220296561 | NON-ORAL MEDICATED CANNABINOID COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT - Disclosed in certain embodiments is a composition for treating nausea and/or vomiting. The composition could be in any form suitable for non-oral administration. The composition may include at least one cannabinoid components, such as cannabidiol and/or cannabigerol, and a ginger component. The composition may include any one of these components or any combination of these components in an effective amount to treat nausea and/or vomiting. Also disclosed herein are methods of preparing a composition to treat nausea and/or vomiting and methods of treating nausea and/or vomiting. | 2022-09-22 |
| 20220296562 | NOVEL NUTRACEUTICAL COMPOSITIONS - The invention relates to nutraceutical compositions comprising dopamine transporter inhibitors and to their use as dietary supplements and food additives. | 2022-09-22 |
| 20220296563 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE - Disclosed herein are acylated active agents (e.g., acylated hydroxybenzoic acid), compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker. | 2022-09-22 |
| 20220296564 | INJECTABLE PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - An injectable pharmaceutical composition comprising an isoxazoline compound of Formula (I), or a salt or N-oxide and moxidectin microspheres and a method of preventing or treating a parasite infestation using the same. | 2022-09-22 |
| 20220296565 | Pharmaceutical compositions of Ovatodiolide and the use thereof - A pharmaceutical composition for anti-viral treatment for papillomavirus associated diseases in mammals, comprising a therapeutically effective amount of Ovatodiolide or Ovatodiolide related substances or an enriched plant extract containing anisomelic acid and ovatiodiolide. The pharmaceutical composition may comprise Ovatodiolide or Ovatodiolide related substances or the enriched extract in an oil-in-water emulsion, for example in an isotropic mixture of at least one oil and at least one surfactant or, alternatively, in a hydrophilic solvent and a co-solvent or surfactant or a combination thereof. A method of treating or preventing papillomavirus associated diseases in a mammal is also provided. | 2022-09-22 |
| 20220296566 | COMBINATION PRODUCT CONTAINING LIMONOID COMPOUND AND ALPHA-GLUCOSIDASE INHIBITOR - The present invention relates to a combination product comprising a limonoid compound (or a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof), and an a-glucosidase inhibitor (e.g., acarbose, acarbose derivative, voglibose, miglitol and the like). The present invention further relates to a use of the combination product for prevention and/or treatment of a disease associated with diabetes and the like. | 2022-09-22 |
| 20220296567 | ORAL DISSOLVABLE FILM THAT INCLUDES PLANT EXTRACT - Films (ODFs) that include botanical extract are provided, as well as methods of making and using the same. | 2022-09-22 |
| 20220296568 | PAMOATE SALT OF MONOAMINE ANTI-PARKINSON'S AGENTS, METHOD OF PREPARATION AND USE THEREOF - In various embodiments, provided herein are pamoate salts of monoamine Anti-Parkinsons disease agents including rotigotine, ropinirole, pramipexole, selegiline, rasagiline, and safinamide, pharmaceutical composition comprising the same, methods of preparing the same, and methods of using the same. For example, the pamoate salt herein can be characterized by a molar ratio of rotigotine, ropinirole, pramipexole, selegiline, rasagiline, or safinamide to pamoic acid of about 1:1 or about 2:1. The pamoate salt herein can also be crystalline including anhydrous, hydrate or solvate forms, or their polymorphs, or amorphous. The pamoate salts described herein can provide a long acting and/or extended release profile of the monoamine agents tor the treatment of Parkinsons disease (PD). Thus, also provided herein are methods of preparing a long acting and/or extended release injectable formulation of the monoamine agents using their respective pamoate salts. And in some embodiments, provided herein are methods of treating a subject in need thereof comprising administering a pharmaceutical composition comprising a pamoate salt of rotigotine, ropinirole, pramipexole, selegiline, rasagiline, and/or safinamide. | 2022-09-22 |
| 20220296569 | COMPOSITION FOR PREVENTING OR TREATING BRAIN-NERVOUS SYSTEM DISEASES COMPRISING RITA OR DERIVATIVES THEREOF - The present invention relates to a composition for preventing or treating central nerve system diseases, and by means of a compound according to one aspect, by inhibiting the death of adult hippocampal neural stem cells caused by stress and preserving the number of neural stem cells, the composition can be utilized in the prevention, amelioration, or treatment of mental diseases or neurodegenerative diseases, or in the prevention or amelioration of stress. | 2022-09-22 |
| 20220296570 | USE OF AMISULPRIDE AS AN ANTI-EMETIC - Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride. | 2022-09-22 |
| 20220296571 | BISDIAZABICYCLO COMPOUND FOR TREATING AND/OR PREVENTING HEPATITIS VIRUS-RELATED DISEASES OR DISORDERS - Disclosed are a bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders, a method for treating and/or preventing hepatitis virus-related diseases or disorders by using the bisdiazabicyclo compound, and a use of the bisdiazabicyclo compound in the preparation of a drug for treating and/or preventing hepatitis virus-related diseases or disorders, and/or eliminating or mitigating hepatitis virus-related diseases or disorders. | 2022-09-22 |
| 20220296572 | IMMUNOSUPPRESSIVE THERAPIES FOR USE WITH CARDIOMYOCYTE CELL THERAPIES, AND ASSOCIATED METHODS AND COMPOSITIONS - Provided are methods and uses related to cardiomyocyte cell therapies involving the administration of immunosuppressive agents for reducing or preventing rejection of administered allogeneic cardiomyocytes. In some embodiments, the methods are for treating a subject with a heart disease or condition in combination with a cardiomyocyte cell therapy. | 2022-09-22 |
| 20220296573 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS - The present invention discloses compounds according to Formula I: | 2022-09-22 |
| 20220296574 | METHODS OF TREATING PROSTATE CANCER - The present application relates generally to methods for treating prostate cancer with substituted tricyclic derivative is 2-[3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-5-[(S)-(oxan-4-yl)(phenyl)methyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol as a bromodomain inhibitor, or the pharmaceutically acceptable salt thereof. | 2022-09-22 |
| 20220296575 | PHARMACEUTICAL COMPOSITIONS - The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy. | 2022-09-22 |
| 20220296576 | DOSING AND EFFECT OF C5a ANTAGONIST WITH ANCA-ASSOCIATED VASCULITIS - The present disclosure provides methods for treating ANCA-associate vasculitis in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of avacopan: | 2022-09-22 |
| 20220296577 | SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases. | 2022-09-22 |
| 20220296578 | AMLODIPINE FORMULATIONS - Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD). | 2022-09-22 |
| 20220296579 | COMPOSITIONS AND METHODS FOR PROVIDING CARDIOPROTECTIVE EFFECTS - The invention provides compositions and methods for providing a cardioprotective effect in a subject. Specifically, the invention provides compositions and methods for treating cardiovascular ailments, for example, ischemia/reperfusion (I/R) injury, cardiac arrhythmias, oxidative stress, or cardiac failure by administering a retinoic acid receptor-beta (RARβ) agonist. | 2022-09-22 |
| 20220296580 | THERAPEUTIC DRUG FOR DISEASES RELATED TO ENDOPLASMIC RETICULUM CELL DEATH IN CORNEAL ENDOTHELIUM - The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGFβ-signal inhibitor. As a preferred TGFβ-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide. | 2022-09-22 |
| 20220296581 | Immunomodulation by IAP Inhibitors - The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided. | 2022-09-22 |
| 20220296582 | METHODS OF DIAGNOSING AND TREATING TOURETTE SYNDROME - Methods and uses for diagnosing and treating Tourette syndrome are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam. | 2022-09-22 |
| 20220296583 | COMPOSITIONS AND METHODS FOR TREATMENT OF OVARIAN AND BREAST CANCER - Provided are methods of treating cancer comprising administering to a patient in need thereof a salt-induced kinase 2 (SIK2) inhibitor and at least a first chemotherapeutic drug. Also provided are methods of increasing or enhancing apoptosis of cancer cells in a patient having cancer, comprising administering to the patient a therapeutically effective amount of a SIK2 inhibitor and at least a first chemotherapeutic drug. Also provided are methods of enhancing sensitivity of ovarian cancer cells to a chemotherapeutic drug or to combinations of chemotherapeutic drugs in a patient having ovarian cancer, comprising contacting the cells with a therapeutically effective amount of a SIK2 inhibitor and at least a first chemotherapeutic drug. A method of increasing or enhancing carboplatin-induced DNA damage in a patient having ovarian cancer, comprising administering to the patient a therapeutically effective amount of a SIK2 inhibitor and at least a first chemotherapeutic drug. | 2022-09-22 |
| 20220296584 | Membrane Active Molecules - A method of inducing anesthesia, sedation, and a method for treating disorders including central nervous system disorder, peripheral nervous system disorder, depression ischemia, and treatment with an anticonvulsant by administering an effective amount of a compound to a subject in need thereof. | 2022-09-22 |
| 20220296585 | OSMOTIC DOSAGE FORMS COMPRISING DEUTETRABENAZINE AND METHODS OF USE THEREOF - Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time. | 2022-09-22 |
| 20220296586 | NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF - Compounds of Formula I: | 2022-09-22 |
